瑞丽医美(02135.HK) 发盈警,预计2024年度亏损约5,900万人民币,相较上年度录得3,200万人民币。持续亏损主要由于计提商誉减值拨备及无形资产减值拨备;购股权开支增加;及加大对附属苏州瑞泉生物研发活动的投入。(de/d)(港股报价延迟最少十五分钟。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/08/30 | 中期业绩 | 无派息 |
2024/03/28 | 末期业绩 | 无派息 |
2024/02/26 | 特别业绩 | 供股: 3股合并后股份供1股@港元 0.1480 |
2024/02/26 | 特别业绩 | 合并:5股合并为1股 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.